Theravance Biopharma Inc

NASDAQ:TBPH   3:59:57 PM EDT
7.08
-0.14 (-1.94%)
Products, Regulatory

Theravance Biopharma Phase 3 Study Of Hypotension Treatment Did Not Meet Main Goal

Published: 09/15/2021 10:23 GMT
Theravance Biopharma Inc (TBPH) - Theravance Biopharma, Inc. Announces Top-line Results From a Phase 3 Study of Ampreloxetine in Patients With Symptomatic Neurogenic Orthostatic Hypotension.
Theravance Biopharma Inc - Randomized, Double-blind, Placebo-controlled Study Did Not Meet Primary Endpoint.
Theravance Biopharma Inc - Majority of Treatment-related Adverse Events Were Mild Or Moderate in Severity.
Theravance - Serious Adverse Events Occurred in Two Patients on Placebo and Four on Ampreloxetine and None Were Considered Related to Study Drug.